Clinical trials: Malaria
Malaria
Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children
The purpose of this study is to assess the safety and immunogenicity of the candidate malaria vaccine in HIV-infected infants and children
- Trial name
- NCT01148459
- Testing
- GSK Biological's Investigational Malaria Vaccine 257049, Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);, Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
- Where
- 2 sites in Kenya
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Malaria
A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate
This is an open-label, multi-centre Phase I/IIa dose escalation blood-stage malaria CHMI trial to assess the safety, immunogenicity and efficacy of the candidate malaria vaccine RH5.1/AS01.
- Trial name
- NCT02927145
- Testing
- RH5.1/ ASO1
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Human Immunodeficiency Virus
Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)
This is a double-blinded, randomized controlled trial of 200 HIV-infected pregnant women living in Tororo, Uganda, an area of high malaria transmission.
- Trial name
- NCT02282293
- Testing
- Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)
- Where
- Uganda
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria, Cerebral
Treating Brain Swelling in Pediatric Cerebral Malaria
This study evaluates the effectiveness of two interventions in Malawian children with cerebral malaria at high risk of death. One-third of the participants will receive treatment as usual, one-third will receive treatment as…
- Trial name
- TBS (NCT03300648)
- Testing
- Mechanical ventilation, Hypertonic saline
- Where
- Malawi
- Volunteers
- 57 people
- Sponsor
- Michigan State University
Malaria, Vivax
A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
This is a prospective, open-label, multicenter, non-comparative, single arm study of pediatric subjects with Plasmodium vivax (P. vivax) malaria, aged 6 months to <16 years of age. A total of 60 subjects will be enrolled.
- Trial name
- NCT02563496
- Testing
- Tafenoquine, Chloroquine
- Where
- 4 sites in Colombia, Vietnam
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Plasmodium Falciparum Malaria
Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Malaria is a disease that affects many people in Africa. Malaria is caused by germs spread by mosquito bites. The purpose of this study is to compare the number of children who get malaria after receiving an experimental malaria…
- Trial name
- NCT00460525
- Testing
- FMP2.1/AS02A, Rabies Vaccine
- Where
- Mali
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Seizure, Epilepsy
A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM
Pediatric cerebral malaria (CM) affects more than 3 million children each year killing ~20% and leaving one third of survivors with long term neurologic and psychiatric sequelae.
- Conditions
- Seizure, Epilepsy, Cerebral Malaria
- Trial name
- LVT2 (NCT01982812)
- Testing
- Oral Levetiracetam, Standard AED
- Where
- Malawi
- Volunteers
- 44 people
- Sponsor
- University of Rochester
Malaria
Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children
This study will investigate the safety and immunogenicity of 2 candidate malaria vaccines administered according to 3 different vaccination schedules in 5 to 17 months old Ghanaian children.
- Trial name
- NCT00360230
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Rabipur
- Where
- 2 sites in Ghana
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
The primary objective of this clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (180:60 mg) with that of standard chloroquine therapy in children and adults with acute…
- Trial name
- NCT04368910
- Testing
- Pyronaridine - artesunate, Chloroquine
- Where
- 2 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults.
- Trial name
- NCT01024686
- Testing
- p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Malaria, Falciparum
Methylene Blue Against Falciparum Malaria in Burkina Faso
Safety of artesunate-amodiaquine combined with methylene blue or primaquine for falciparum malaria treatment in African children: A randomised controlled trial Elimination has become the goal of malaria programmes in an…
- Trial name
- BlueACTn (NCT02851108)
- Testing
- Methylene Blue, Primaquine
- Where
- Burkina Faso
- Volunteers
- 100 people
- Sponsor
- Heidelberg University
Malaria,Falciparum, Parasitemia
Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
This is a single-centre, open-label, Phase Ib study designed to assess if intravenous injection of approximately 3200 P. falciparum (NF54 strain) sporozoites can be safely administered to achieve blood-stage parasitaemia with a…
- Conditions
- Malaria,Falciparum, Parasitemia, Protozoan Infections, Parasitic Disease
- Trial name
- NCT04310085
- Testing
- Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet, PfSPZ-DVI Challenge
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
HIV, Pregnancy Malaria
A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV
More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk.
- Conditions
- HIV, Pregnancy Malaria, Sexually Transmitted Infection
- Trial name
- PREMISE (NCT03431168)
- Testing
- Azithromycin/TMPS
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- University of Alabama at Birmingham
Malaria, Falciparum Malaria
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
An antimalarial drug efficacy trial was conducted for artemether-lumefantrine (AL) and chloroquine (CQ) in the three (3) municipalities (Bataraza, Brookes and Rizal) of Palawan.
- Conditions
- Malaria, Falciparum Malaria, Vivax Malaria, Malaria Recrudescence
- Trial name
- TES (NCT04222088)
- Testing
- Arthemeter-lumefantrine, Chloroquine, Primaquine
- Volunteers
- 159 people
- Sponsor
- Research Institute for Tropical Medicine, Philippines
Malaria
Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda
This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) + dihydroartemisin-piperaquine (DP) will significantly reduce the risk of adverse birth outcomes…
- Trial name
- NCT04336189
- Testing
- Sulfadoxine-pyrimethamine (SP), Dihydroartemisinin-piperaquine (DP)
- Where
- Uganda
- Volunteers
- 2,757 people, healthy volunteers welcome
- Sponsor
- Grant Dorsey, M.D, Ph.D.
Malaria
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
This is a study in which healthy adult volunteers will be given either an experimental Malaria vaccine or a saline control vaccine. Each volunteer will receive three vaccinations in total.
- Trial name
- NCT02925403
- Testing
- R21/Matrix-M1, Saline
- Where
- Burkina Faso
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Safety and Efficacy Study of IV Artesunate to Treat Malaria
The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
- Trial name
- NCT00298610
- Testing
- Artesunate, Malarone
- Where
- Kenya
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria,Falciparum
Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults
Malaria remains one of the leading causes of morbidity and mortality worldwide. Plasmodium falciparum is a complex pathogen with numerous immune evasion mechanisms which has added layers of complexity to the development of safe…
- Trial name
- R21/Matrix-M (NCT05252845)
- Testing
- R21/Matrix-M vaccination, DHA-PIP, PQ
- Where
- Thailand
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children
The purpose of this study is to show the consistency of different lots of a candidate vaccine (257049) against malaria developed by GlaxoSmithKline (GSK) Biologicals.
- Trial name
- NCT01323972
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
- Where
- 2 sites in Nigeria
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline